| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 20 | 2023 | 1723 | 2.190 |
Why?
|
| Genome-Wide Association Study | 11 | 2024 | 423 | 1.390 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 734 | 1.190 |
Why?
|
| Quantitative Trait Loci | 2 | 2017 | 88 | 0.860 |
Why?
|
| Colorectal Neoplasms | 5 | 2018 | 512 | 0.820 |
Why?
|
| DNA Copy Number Variations | 2 | 2013 | 37 | 0.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 968 | 0.700 |
Why?
|
| Dance Therapy | 1 | 2019 | 4 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 39 | 0.570 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 863 | 0.550 |
Why?
|
| Computer Simulation | 3 | 2017 | 408 | 0.550 |
Why?
|
| Adiposity | 3 | 2025 | 157 | 0.540 |
Why?
|
| Carcinoma, Lobular | 2 | 2008 | 5 | 0.520 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 31 | 0.510 |
Why?
|
| Receptors, Estrogen | 4 | 2021 | 183 | 0.510 |
Why?
|
| CpG Islands | 4 | 2024 | 109 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 220 | 0.490 |
Why?
|
| Registries | 1 | 2018 | 437 | 0.490 |
Why?
|
| Carcinoma | 2 | 2015 | 108 | 0.470 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 3 | 0.450 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2015 | 4 | 0.450 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2015 | 27 | 0.450 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 81 | 0.430 |
Why?
|
| Genetic Variation | 1 | 2017 | 430 | 0.430 |
Why?
|
| Middle Aged | 21 | 2025 | 12222 | 0.410 |
Why?
|
| Humans | 40 | 2025 | 43102 | 0.400 |
Why?
|
| Exercise | 1 | 2019 | 692 | 0.400 |
Why?
|
| Female | 29 | 2025 | 24698 | 0.380 |
Why?
|
| Aged | 17 | 2025 | 8214 | 0.380 |
Why?
|
| DNA Methylation | 6 | 2024 | 403 | 0.360 |
Why?
|
| Adenoma | 1 | 2013 | 96 | 0.360 |
Why?
|
| Connexin 43 | 5 | 1999 | 41 | 0.350 |
Why?
|
| Colon | 1 | 2012 | 120 | 0.340 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 223 | 0.330 |
Why?
|
| Adult | 13 | 2021 | 13872 | 0.300 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 21 | 0.300 |
Why?
|
| Hydroxycholesterols | 2 | 2025 | 18 | 0.280 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 1092 | 0.270 |
Why?
|
| Phenotype | 6 | 2025 | 780 | 0.270 |
Why?
|
| Mammary Glands, Human | 2 | 2018 | 40 | 0.260 |
Why?
|
| Hawaii | 6 | 2022 | 2011 | 0.260 |
Why?
|
| Gap Junctions | 2 | 1999 | 49 | 0.260 |
Why?
|
| Drosophila Proteins | 3 | 2005 | 188 | 0.260 |
Why?
|
| Mutation | 3 | 2020 | 1177 | 0.260 |
Why?
|
| Transcription Factors | 3 | 2005 | 735 | 0.240 |
Why?
|
| Repressor Proteins | 2 | 2005 | 273 | 0.230 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 561 | 0.230 |
Why?
|
| DNA, Neoplasm | 4 | 2012 | 92 | 0.230 |
Why?
|
| Postmenopause | 2 | 2025 | 141 | 0.220 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2025 | 55 | 0.220 |
Why?
|
| Gene Expression | 3 | 2018 | 701 | 0.220 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 193 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2025 | 1759 | 0.200 |
Why?
|
| Alleles | 3 | 2017 | 352 | 0.200 |
Why?
|
| Case-Control Studies | 6 | 2023 | 1285 | 0.190 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 374 | 0.190 |
Why?
|
| Bacterial Toxins | 1 | 2023 | 50 | 0.190 |
Why?
|
| Cyanobacteria | 1 | 2023 | 27 | 0.190 |
Why?
|
| Intra-Abdominal Fat | 1 | 2023 | 46 | 0.190 |
Why?
|
| Oncogene Protein pp60(v-src) | 2 | 1999 | 10 | 0.190 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 5 | 0.180 |
Why?
|
| Pancreas | 1 | 2021 | 45 | 0.170 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 92 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 934 | 0.170 |
Why?
|
| Relaxin | 1 | 2020 | 10 | 0.170 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 15 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 163 | 0.170 |
Why?
|
| Hypothyroidism | 1 | 2020 | 26 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 24 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 94 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 224 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 50 | 0.160 |
Why?
|
| Incidence | 2 | 2022 | 1078 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 760 | 0.150 |
Why?
|
| Anthropometry | 1 | 2019 | 97 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2019 | 760 | 0.140 |
Why?
|
| Vimentin | 1 | 2018 | 44 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 310 | 0.140 |
Why?
|
| Protein Isoforms | 1 | 2018 | 139 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2015 | 61 | 0.140 |
Why?
|
| Gene Dosage | 3 | 2015 | 75 | 0.140 |
Why?
|
| Genetic Loci | 2 | 2015 | 104 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 121 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 100 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 31 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2024 | 518 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 154 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1996 | 139 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 140 | 0.130 |
Why?
|
| Organ Specificity | 1 | 2017 | 141 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 704 | 0.120 |
Why?
|
| Young Adult | 3 | 2019 | 5080 | 0.120 |
Why?
|
| Prognosis | 4 | 2021 | 861 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 7 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2015 | 8 | 0.120 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 34 | 0.120 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1995 | 9 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2015 | 15 | 0.120 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 25 | 0.110 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2005 | 70 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 28 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 3994 | 0.110 |
Why?
|
| Qb-SNARE Proteins | 1 | 2014 | 2 | 0.110 |
Why?
|
| Gene Frequency | 2 | 2015 | 206 | 0.110 |
Why?
|
| Computational Biology | 1 | 2017 | 327 | 0.110 |
Why?
|
| Cluster Analysis | 2 | 2015 | 207 | 0.110 |
Why?
|
| Quality of Life | 1 | 2019 | 616 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2005 | 411 | 0.100 |
Why?
|
| Phosphorylation | 6 | 2019 | 986 | 0.100 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 80 | 0.100 |
Why?
|
| Allelic Imbalance | 1 | 2013 | 4 | 0.100 |
Why?
|
| Male | 9 | 2023 | 23409 | 0.100 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 61 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 291 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2021 | 587 | 0.100 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 48 | 0.100 |
Why?
|
| Drosophila | 2 | 2004 | 152 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2018 | 2157 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 14 | 0.090 |
Why?
|
| Obesity | 2 | 2023 | 1151 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 25 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 62 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 150 | 0.090 |
Why?
|
| Choline | 1 | 2012 | 61 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 93 | 0.090 |
Why?
|
| Smoking | 1 | 2018 | 1024 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2005 | 296 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 245 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2853 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 220 | 0.080 |
Why?
|
| Peptide Mapping | 3 | 1999 | 20 | 0.070 |
Why?
|
| Protein Binding | 2 | 2005 | 1082 | 0.070 |
Why?
|
| Animals | 10 | 2019 | 16992 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 587 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2024 | 291 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 518 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 1600 | 0.070 |
Why?
|
| Recurrence | 2 | 2021 | 152 | 0.070 |
Why?
|
| Nicotine | 2 | 2024 | 302 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1067 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1154 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1999 | 196 | 0.060 |
Why?
|
| Glutathione Transferase | 2 | 2005 | 90 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 652 | 0.060 |
Why?
|
| Risk | 2 | 2018 | 287 | 0.060 |
Why?
|
| Mammography | 2 | 2018 | 212 | 0.060 |
Why?
|
| Japan | 2 | 2018 | 348 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2005 | 20 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 51 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3156 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2025 | 25 | 0.060 |
Why?
|
| Dimerization | 1 | 2005 | 112 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 116 | 0.060 |
Why?
|
| Body Size | 1 | 2005 | 49 | 0.060 |
Why?
|
| Cell Separation | 1 | 2005 | 94 | 0.060 |
Why?
|
| DNA | 2 | 2005 | 592 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2005 | 94 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2005 | 183 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 2676 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 209 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 125 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 423 | 0.050 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 24 | 0.050 |
Why?
|
| Genotype | 2 | 2018 | 800 | 0.050 |
Why?
|
| Insulin | 1 | 2005 | 258 | 0.050 |
Why?
|
| Longevity | 1 | 2005 | 173 | 0.050 |
Why?
|
| Marine Toxins | 1 | 2023 | 17 | 0.050 |
Why?
|
| Microcystins | 1 | 2023 | 8 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 93 | 0.050 |
Why?
|
| Precipitin Tests | 2 | 1999 | 52 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 592 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 211 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2005 | 281 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2021 | 9 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2021 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 20 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 526 | 0.040 |
Why?
|
| Phylogeny | 1 | 2005 | 769 | 0.040 |
Why?
|
| Base Sequence | 3 | 2004 | 983 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 1081 | 0.040 |
Why?
|
| Time Factors | 1 | 2005 | 1857 | 0.040 |
Why?
|
| Cell Division | 2 | 2015 | 311 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 232 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 199 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 355 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 95 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 11 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2015 | 1604 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1455 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 368 | 0.040 |
Why?
|
| Phosphopeptides | 2 | 1996 | 5 | 0.040 |
Why?
|
| Spodoptera | 2 | 1996 | 16 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 1999 | 224 | 0.040 |
Why?
|
| Smad7 Protein | 1 | 2018 | 5 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1997 | 1542 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 925 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 69 | 0.040 |
Why?
|
| src Homology Domains | 1 | 1997 | 14 | 0.030 |
Why?
|
| Tyrosine | 1 | 1997 | 120 | 0.030 |
Why?
|
| Mice | 2 | 2019 | 6644 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 216 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 515 | 0.030 |
Why?
|
| Rats | 3 | 1999 | 3735 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 41 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 358 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 665 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 667 | 0.030 |
Why?
|
| Baculoviridae | 1 | 1995 | 12 | 0.030 |
Why?
|
| United States | 2 | 2018 | 5205 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1995 | 29 | 0.030 |
Why?
|
| Metabolome | 1 | 2015 | 51 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 103 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 102 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 53 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1995 | 68 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 75 | 0.030 |
Why?
|
| Metabolomics | 1 | 2015 | 95 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 165 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 47 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 758 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2544 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1995 | 456 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 465 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1995 | 307 | 0.020 |
Why?
|
| RNA | 1 | 2015 | 266 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1995 | 883 | 0.020 |
Why?
|
| Overweight | 1 | 2015 | 249 | 0.020 |
Why?
|
| Liver | 1 | 1996 | 511 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2012 | 10 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 27 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1596 | 0.020 |
Why?
|
| Electrophoresis, Microchip | 1 | 2012 | 21 | 0.020 |
Why?
|
| Taxoids | 1 | 2012 | 50 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 655 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1995 | 1621 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 440 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 575 | 0.020 |
Why?
|
| DNA Primers | 2 | 2004 | 294 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2005 | 15 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 61 | 0.010 |
Why?
|
| X Chromosome | 1 | 2004 | 30 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 1180 | 0.010 |
Why?
|
| Larva | 1 | 2004 | 133 | 0.010 |
Why?
|
| Genes, Suppressor | 1 | 2003 | 3 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2003 | 17 | 0.010 |
Why?
|
| DNA Replication | 1 | 2004 | 148 | 0.010 |
Why?
|
| Cell Line | 2 | 1997 | 1410 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2003 | 63 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 300 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 333 | 0.010 |
Why?
|
| Proline | 1 | 1997 | 40 | 0.010 |
Why?
|
| Trypsin | 1 | 1996 | 40 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1996 | 78 | 0.010 |
Why?
|
| Epithelium | 1 | 1996 | 78 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 186 | 0.010 |
Why?
|
| Transfection | 1 | 1996 | 532 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 455 | 0.010 |
Why?
|